Immatics N.V. (NASDAQ:IMTX) Given Consensus Rating of "Buy" by Brokerages

Immatics N.V. (NASDAQ:IMTX - Get Free Report) has received a consensus rating of "Buy" from the five ratings firms that are currently covering the stock, MarketBeat.com reports. Four equities research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $14.67.

IMTX has been the topic of a number of analyst reports. Wall Street Zen downgraded Immatics from a "hold" rating to a "strong sell" rating in a research report on Thursday, May 22nd. Deutsche Bank Aktiengesellschaft initiated coverage on Immatics in a research report on Wednesday, May 28th. They set a "buy" rating and a $10.00 price target on the stock. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Immatics in a research report on Tuesday, April 1st.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Suvretta Capital Management LLC bought a new position in Immatics during the 4th quarter worth $36,014,000. T. Rowe Price Investment Management Inc. grew its holdings in Immatics by 38.4% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 14,677,003 shares of the company's stock worth $66,194,000 after acquiring an additional 4,072,226 shares during the period. Vestal Point Capital LP grew its holdings in Immatics by 67.3% during the 4th quarter. Vestal Point Capital LP now owns 6,275,000 shares of the company's stock worth $44,615,000 after acquiring an additional 2,525,000 shares during the period. Braidwell LP grew its holdings in Immatics by 112.7% during the 4th quarter. Braidwell LP now owns 3,503,965 shares of the company's stock worth $24,913,000 after acquiring an additional 1,856,400 shares during the period. Finally, Paradigm Biocapital Advisors LP grew its holdings in Immatics by 38.7% during the 4th quarter. Paradigm Biocapital Advisors LP now owns 5,414,409 shares of the company's stock worth $38,496,000 after acquiring an additional 1,509,547 shares during the period. 64.41% of the stock is currently owned by institutional investors.

Immatics Stock Down 4.1%

Shares of Immatics stock traded down $0.24 on Friday, hitting $5.61. The stock had a trading volume of 709,358 shares, compared to its average volume of 662,617. Immatics has a twelve month low of $3.30 and a twelve month high of $13.09. The business's 50 day moving average is $5.11 and its two-hundred day moving average is $5.35. The stock has a market cap of $681.90 million, a price-to-earnings ratio of -33.00 and a beta of 0.83.

Immatics (NASDAQ:IMTX - Get Free Report) last posted its earnings results on Tuesday, May 13th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.04. Immatics had a negative return on equity of 4.52% and a negative net margin of 14.73%. The company had revenue of $20.12 million for the quarter, compared to the consensus estimate of $14.92 million. As a group, equities analysts predict that Immatics will post -0.72 earnings per share for the current fiscal year.

Immatics Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.